Dr. Athena M. Countouriotis M.D.

Turning Point Therapeutics

Dr. Athena Countouriotis, President, CEO, and board member of Turning Point Therapeutics has broad oncology biotech leadership experience, guiding multiple development programs to approval. Her experience includes large and small molecule therapeutics in hematologic and solid tumor indications, with multiple regulatory approvals in the U.S. and Europe. She joined Turning Point Therapeutics in May 2018 as executive vice president and chief medical officer to advance the clinical development of repotrectinib. Athena previously served as senior vice president and chief medical officer for Adverum Biotechnologies, and before that as senior vice president and chief medical officer of Halozyme Therapeutics. She received her M.D. from Tufts University School of Medicine and her bachelor’s degree from the University of California, Los Angeles.

Year appointed: 2018